Work at the Department
Transfusion department (Department) provides patients admitted to the ICVD “Dedinje” for hospital treatment with the following:
- effective and safe chemotherapy in the perioperative period of surgical interventions;
- immunohematological tests – determining blood types, performing transfusion crossmatching, testing irregular anti-erythrocyte antibodies, erythrocyte phenotyping;
- hemostatic tests – examining platelet function, determining the concentration of hemostatically active factors, performing “screening” tests;
- preparation/therapeutic use of specific blood components – washed erythrocytes (intraoperative autologous blood salvage of), fibrin glue, etc.;
- apheresis procedures,collection / therapeutic use of stem cells.
The selection and dosage of blood components and the duration of chemotherapy depend on the results of these tests. By improving existing and introducing new diagnostic and therapeutic procedures, it is possible to achieve a better performance, while maintaining / increasing the safety of chemotherapy – while minimizing the occurrence of side effects / complications and other adverse effects of blood component treatment.
The Department employs:
- three doctors– head of department, specialist – transfusiologist, subspecialist – hematologist or specialist – transfusiologist, subspecialist – clinical transfusiologist and two department doctors – specialist – transfusiologist (subspecialist – clinical transfusiologist);
- one health care associate;
- chief medical technician (BSc) and
- 7medical technicians – transfusionists (BSc, Medical College and HS).
List of procedures
Clinical transfusiology and treatment with blood components
- Providing blood components for surgical treatment
- Storing blood components in optimal temperature conditions
- Quality control and maintenance of blood components
- Monitoring the effects of blood component therapy
- Prevention/care in case of side effects and complications of blood component therapy
- Participation treating patients with anemic syndrome with the use of iron preparations (intravenous and oral) and cytokine erythropoiesis stimulators
- Control of anticoagulant, antiplatelet and fibrinolytic therapy
- Determination of blood type (ABO and Rhesus systems)
- Performing an antihuman globulin (AHG or Coombs) test – direct AHG test (DAT) and indirect AHG test (IAT)
- Detection, identification and quantification of irregular antierythrocyte antibodies
- Erythrocyte antigens typing (hemophenotyping) and selection of compatible blood
- Immunohematological pretransfusion tests – cross-compatibility test
Perioperative monitoring of hemostasis
- ROTEM provides insight into the coagulation-fibrinolysis process, monitoring the formation and lysis of clots, as well as assessing the share of platelets and fibrinogen when establishing the hemostasis. Rotem enables streamlined chemotherapy – concentrated coagulation factors/inhibitors, antifibrinolytics, etc. Rotem provides insight and ensures assessment of hemostasis status after only 10-15 minutes.
- MULTIPLATE analyzer is used to examine the basic (physiological) function of platelets, as well as to assess the effect of antiplatelet drugs. There are various drugs in use whose effect is being tested: 1) cyclooxygenase inhibitors; 2) ADP receptor antagonists; 3) GPIIbIIIa receptor inhibitors.
- COAGULATION TESTS include testing of prothrombin time (PT/INR), activated partial thromboplastin time (aPTT), D-dimer, antithrombin III (AT-III), anti-Xa factor etc.
Application of autologous blood donation strategy in therapy
- Preoperative collection of autologous blood;
- Acute normovolemic hemodilution – replacement of circulating volume with crystalloid/colloidal solutions;
- Intraoperative blood/erythrocyte salvage;
- Preparation of specific blood components – autologous fibrin glue.
Instructions for patients
The department works 24/7 for all patients admitted for hospital treatment.
011 360 1657
0 –24 h
Telephone: 011 360 1657